comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-28 12:08:42 - browse：9

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Breakthrough Alzheimer’s drugs are inaccessible in rural states

Wikipedia

focus

WSS

For BCIs, commercial hurdles may be bigger than scientific ones

‘Oppenheimer’ and the risks of AI in health care

Mega Millions pot grows to $1.25 billion after no winner

Sage hopes for a blockbuster in antidepressant now before FDA

Wildfire pollution widens asthma inequities on Long Island

A cyberattack has disrupted hospitals and health care in several states

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Physician groups backed by private equity giant lobby on mergers

Guidelines to prevent youth baseball injuries need more muscle

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Psychedelics group wrestles with new pharma identity

Microsoft strikes partnership with Duke Health to advance health AI

Moonlake's readout produced a cash windfall. Risks remain

The high personal cost of affirmative action for Black doctors

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Biden calls for immediate release of Niger's president amid apparent coup

entertainment

Stem cell clinics for heart failure: buyer be wary

What the US credit downgrade means for the economy, your finances

Dramatically reducing cancer deaths requires the PASTEUR Act

Verily hires former Apple Health leader as chief scientific officer

Physician groups backed by private equity giant lobby on mergers

Sage hopes for a blockbuster in antidepressant now before FDA

Wikipedia

focus

leisure time

leisure time